We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

93 hedge funds and large institutions have $443M invested in Avadel Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 18 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

264% more call options, than puts

Call options by funds: $17.4M | Put options by funds: $4.8M

250% more funds holding in top 10

Funds holding in top 10: 2 → 7 (+5)

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

100% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 18

85% more capital invested

Capital invested by funds: $239M → $443M (+$203M)

24.24% more ownership

Funds ownership: 54.15% → 78.39% (+24%)

12% more funds holding

Funds holding: 83 → 93 (+10)

Holders
93
Holders Change
+10
Holders Change %
+12.05%
% of All Funds
1.48%
Holding in Top 10
7
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+250%
% of All Funds
0.11%
New
19
Increased
36
Reduced
18
Closed
9
Calls
$17.4M
Puts
$4.8M
Net Calls
+$12.6M
Net Calls Change
+$11.2M

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$46.2M
2
PCH
Polar Capital Holdings
United Kingdom
+$14.5M
3
WP
Woodline Partners
California
+$10.4M
4
VC
Vivo Capital
California
+$8.28M
5
SB
Samsara BioCapital
California
+$6.17M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2.63M
2
PVI
Pura Vida Investments
New York
-$1.86M
3
BIP
Brandes Investment Partners
California
-$1.73M
4
KCM
Knoll Capital Management
Florida
-$1.23M
5
CSS
Cubist Systematic Strategies
Connecticut
-$887K
Name Holding Trade Value Shares
Change 		Change in
Stake
DMKJ
26
David M. Knott Jr
$2.67M -$157K -19,138 -6%
Millennium Management
27
Millennium Management
New York
$2.65M -$2.63M -320,426 -53%
PCM
28
Portolan Capital Management
Massachusetts
$2.64M +$2.37M +288,325 New
MIM
29
Monashee Investment Management
Massachusetts
$2.52M +$2.26M +275,000 New
Ameriprise
30
Ameriprise
Minnesota
$2.02M +$776K +94,421 +75%
JGC
31
J. Goldman & Co
New York
$1.66M +$878K +106,750 +144%
EWM
32
Edge Wealth Management
New York
$1.55M – – –
CIBC Private Wealth Group
33
CIBC Private Wealth Group
Georgia
$1.31M +$33.5K +4,080 +3%
IAMOG
34
Investors Asset Management of Georgia
Georgia
$1.2M -$61.7K -7,500 -5%
CM
35
Caption Management
Oklahoma
$1.06M +$950K +115,504 New
Group One Trading
36
Group One Trading
Illinois
$1.03M +$709K +86,290 +323%
Two Sigma Investments
37
Two Sigma Investments
New York
$1M -$77.8K -9,460 -8%
Two Sigma Advisers
38
Two Sigma Advisers
New York
$968K +$104K +12,600 +14%
SC
39
Schulhoff & Co
Ohio
$879K – – –
State Street
40
State Street
Massachusetts
$865K +$84.6K +10,286 +12%
Geode Capital Management
41
Geode Capital Management
Massachusetts
$733K +$7.6K +924 +1%
Goldman Sachs
42
Goldman Sachs
New York
$480K +$198K +24,050 +85%
CSS
43
Cubist Systematic Strategies
Connecticut
$452K -$887K -107,885 -69%
BlackRock
44
BlackRock
New York
$432K +$73K +8,881 +23%
TI
45
Trexquant Investment
Connecticut
$389K +$349K +42,435 New
MML Investors Services
46
MML Investors Services
Massachusetts
$322K +$8.22K +1,000 +3%
SOW
47
State of Wyoming
Wyoming
$246K -$18.1K -2,207 -8%
Jane Street
48
Jane Street
New York
$237K -$403K -49,000 -65%
VCIM
49
Velan Capital Investment Management
Georgia
$236K +$212K +25,743 New
OC
50
Oppenheimer & Co
New York
$214K +$192K +23,358 New
1
2
3 4 5

AVDL Hedge Fund Activity: Q1 2023 in Review

93 of the 6,278 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q1 2023, worth a combined $443M — up 85% from $239M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new AVDL positions and 9 closed out — a net gain of 10 holders — while 36 added to existing stakes and 18 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $46.2M. The largest seller was Millennium Management, cutting an estimated $2.63M.

  • 93 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q1 2023, up from 83 in Q4 2022.
  • Funds reported $443M of Avadel Pharmaceuticals stock for Q1 2023, up 85% quarter-over-quarter.
  • 19 funds opened new Avadel Pharmaceuticals positions in Q1 2023 and 9 closed out, a net change of +10 holders.
  • The largest Avadel Pharmaceuticals buyer in Q1 2023 was Janus Henderson Group, an estimated $46.2M added.
  • The largest Avadel Pharmaceuticals seller in Q1 2023 was Millennium Management, an estimated $2.63M sold.

Based on aggregated 13F filings for Q1 2023.